Table 2.
Day 22 | Day 35 | Day 43 | Day 50 | |
---|---|---|---|---|
Percent change in EASI from baseline, mean ± SD | −47.46 ± 22.775 | −59.26 ± 37.646 | −80.78 ± 15.076 | −87.15 ± 13.396 |
Patients achieving EASI‐50, n (%) | 7 (50.0) | 11 (78.6) | 13 (92.9) | 13 (92.9) |
Patients achieving EASI‐75, n (%) | 0 | 6 (42.9) | 10 (71.4) | 11 (78.6) |
Patients achieving EASI‐90, n (%) | 0 | 1 (7.1) | 5 (35.7) | 7 (50.0) |
Patients achieving IGA 0 or 1, n (%) | 0 | 1 (7.1) | 4 (28.6) | 7 (50.0) |
Percent change in AD affected body surface area from baseline, mean ± SD | −25.91 ± 29.182 | −37.40 ± 52.202 | −62.67 ± 23.553 | −74.82 ± 24.170 |
Results were based on all observed values. N = 13 for all measurements except for Day 35 (n = 14). AD, atopic dermatitis; EASI, Eczema Area and Severity Index; EASI‐50, ≥ 50% reduction in EASI from baseline; EASI‐75, ≥ 75% reduction in EASI from baseline; EASI‐90, ≥ 90% reduction in EASI from baseline; IGA, Investigator's Global Assessment; SD, standard deviation.